
Medicine and Health
Efficacy and safety of serplulimab plus nab-paclitaxel in previously treated patients with PD-L1-positive advanced cervical cancer: a phase II, single-arm study
J. An, X. Li, et al.
This phase II study explored the combination of serplulimab and nab-paclitaxel in previously treated patients with PD-L1-positive advanced cervical cancer, achieving an impressive 57.1% objective response rate and demonstrating durable clinical activity with manageable safety. Conducted by esteemed authors including Jusheng An and Xiumin Li, this research opens new avenues for cervical cancer treatment.
Playback language: English
Related Publications
Explore these studies to deepen your understanding of the subject.